Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Stoke Therapeutics, Inc. - Common Stock (NQ:STOK)

26.07 +0.07 (+0.25%)
Streaming Delayed Price Updated: 10:05 AM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 64,926
Open 26.06
Bid (Size) 26.00 (100)
Ask (Size) 26.10 (100)
Prev. Close 26.00
Today's Range 25.91 - 26.42
52wk Range 20.32 - 40.22
Shares Outstanding 44,188,534
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics, Inc.
Via Business Wire

Performance

YTD
-15.6%
-15.6%
1 Month
-16.5%
-16.5%
3 Month
-20.3%
-20.3%
6 Month
-18.5%
-18.5%
1 Year
+10.9%
+10.9%

More News

Read More
News headline image
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
From Biogen Inc.
Via GlobeNewswire
Stoke Therapeutics (NASDAQ:STOK) Beats Q1 2026 Estimates as Phase 3 Trial Nears Completion ↗
Via Chartmill
News headline image
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics to Present at the Cantor Global Healthcare Conference
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
From Biogen Inc.
Via GlobeNewswire
News headline image
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics’ Dravet Trial Tops Enrollment Target With Zero Dropouts ↗
Via MarketBeat
News headline image
Stoke Therapeutics (STOK) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics to Present at Upcoming Investor Conferences in June
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics
Via Business Wire
News headline image
Stoke Therapeutics Q1 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial Updates
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics, Inc.
Via Business Wire

Frequently Asked Questions

Is Stoke Therapeutics, Inc. - Common Stock publicly traded?
Yes, Stoke Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Stoke Therapeutics, Inc. - Common Stock trade on?
Stoke Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Stoke Therapeutics, Inc. - Common Stock?
The ticker symbol for Stoke Therapeutics, Inc. - Common Stock is STOK on the Nasdaq Stock Market
What is the current price of Stoke Therapeutics, Inc. - Common Stock?
The current price of Stoke Therapeutics, Inc. - Common Stock is 26.07
When was Stoke Therapeutics, Inc. - Common Stock last traded?
The last trade of Stoke Therapeutics, Inc. - Common Stock was at 10/01/26 10:05 AM ET
What is the market capitalization of Stoke Therapeutics, Inc. - Common Stock?
The market capitalization of Stoke Therapeutics, Inc. - Common Stock is 1.15B
How many shares of Stoke Therapeutics, Inc. - Common Stock are outstanding?
Stoke Therapeutics, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.